BRIEF-Vanda Pharmaceuticals Confirms Rejection Of Unsolicited Takeover Proposals From Future Pak-March 2024-www.financetom.com

BRIEF-Vanda Pharmaceuticals Confirms Rejection Of Unsolicited Takeover Proposals From Future Pak

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Vanda Pharmaceuticals Confirms Rejection Of Unsolicited Takeover Proposals From Future Pak

Apr 17, 2024 6:40 AM

April 17 (Reuters) - Vanda Pharmaceuticals Inc ( VNDA ):

* VANDA PHARMACEUTICALS CONFIRMS REJECTION OF UNSOLICITED

TAKEOVER

PROPOSALS FROM FUTURE PAK

* VANDA PHARMACEUTICALS INC ( VNDA ) - BOARD DETERMINED UNSOLICITED

TAKEOVER PROPOSALS SIGNIFICANTLY UNDERVALUE COMPANY

Source text for Eikon:

Further company coverage:

Previous page： Nortech Systems Q3 net loss narrows due to restructuring efforts Next page： DiamondRock Hospitality to Transfer Listing to Nasdaq From NYSE

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Nortech Systems Q3 net loss narrows due to restructuring efforts

Nov 13, 2025

Overview * Nortech Q3 2025 net sales decline 2.9% yr/yr to $30.5 mln * Net loss narrows to $146,000 in Q3 2025 from $739,000 in Q3 2024 * Adjusted EBITDA rises to $1.3 mln in Q3 2025 from $0.1 mln in Q3 2024 Outlook * Company highlights AS9100:D certification at Monterrey facility enhancing aerospace offerings * Nortech ( NSYS )...

DiamondRock Hospitality to Transfer Listing to Nasdaq From NYSE

Nov 13, 2025

08:14 AM EST, 11/13/2025 (MT Newswires) -- DiamondRock Hospitality ( DRH ) said Thursday it will voluntarily transfer its class A common shares listing to Nasdaq from the New York Stock Exchange. The company said it anticipates its common shares to start trading on the Nasdaq Global Select Market on Dec. 1, under the current DRH ticker. ...

Genetic medicines firm MeiraGTx misses Q3 revenue expectations, net loss widens

Nov 13, 2025

Overview * MeiraGTx ( MGTX ) Q3 revenue misses analyst expectations, declining significantly from last year * Company enters strategic collaboration with Eli Lilly, including $75 mln upfront payment * Net loss widens to $50.5 mln in Q3, driven by increased R&D expenses Outlook * Company anticipates Phase 2 data for AAV-hAQP1 in early 2027 * MeiraGTx ( MGTX )...

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025

FRANKFURT, Nov 13 (Reuters) - BioNTech said on Thursday that its collaboration with Pfizer ( PFE ) has not changed, when asked to comment on a report that Pfizer ( PFE ) is looking to sell its stake in the German biotech firm. We continue to have a close and strong collaboration, a spokesperson said in a statement, adding that...